News stories about Ritter Pharmaceuticals (NASDAQ:RTTR) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ritter Pharmaceuticals earned a news sentiment score of 0.05 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.6825574548202 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
A number of research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a research note on Tuesday, September 19th. Roth Capital set a $2.00 price target on shares of Ritter Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 23rd. Finally, HC Wainwright cut their price target on shares of Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating on the stock in a report on Monday, October 23rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $2.10.
Ritter Pharmaceuticals (NASDAQ:RTTR) remained flat at $$0.35 during trading hours on Friday. The stock had a trading volume of 600,621 shares, compared to its average volume of 349,100. The company has a market capitalization of $16.98 and a P/E ratio of -0.30. Ritter Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $3.75.
Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14). analysts anticipate that Ritter Pharmaceuticals will post -0.76 earnings per share for the current fiscal year.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.